Healthcare
ByCan Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
Can Insilico Medicine and China Medical System Accelerate AI-Discovered Drugs from Algorithm to Clinic?
Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China Medical System Holdings…
Can Angelini’s $120M AI Alliance with Quiver Bioscience Redefine Drug Discovery in Genetic Epilepsies?
Executive SummaryIn a strategic push to strengthen its neuroscience pipeline, Angelini Pharma has entered a multiyear collaboration with…
How Does Merck Architect a $70 Billion Post-Keytruda Fortress Through 2030?
Merck executes a “One Pipeline” diversification masterplan, tripling late-stage assets since 2021 to deliver 20+ potential blockbusters offsetting Keytruda’s…
How Does Sanofi Transform Immunology Dominance Into €20+ Billion Revenue Through 2030?
Sanofi masterminds a “multi-indication immunology powerhouse” strategy, surgically channeling R&D toward 12 blockbuster candidates (3 “pipeline-in-a-product” assets exceeding €5B peak…
